Other Clinical Trial - Study of BMS-936558 (Nivolumab) Compared to

Clinical Trial Description

CheckMate 057: CHECKpoint pathway and nivoluMAb clinical Trial Evaluation 057 ;

Study Design

Related Conditions & MeSH terms

Carcinoma, Non-Small-Cell Lung
Lung Neoplasms
Non-Squamous Cell Non-small Cell Lung Cancer

See also
Status	Clinical Trial	Phase
Recruiting	`NCT03790228` - Anlotinib Combined With Pemetrexed And Carboplatin as First-line Treatment in Advanced Nonsquamous NSCLC	Phase 1
Recruiting	`NCT03778138` - Study of Anlotinib Combined With Pemetrexed in Patients With Advanced Nonsquamous NSCLC	Phase 2
Not yet recruiting	`NCT03792074` - To Evaluate the Efficacy and Safety of SCT510 in the Treatment of Non-small Cell Lung Cancer	Phase 3

See also

Status

Clinical Trial

Phase

Recruiting

NCT03790228 - Anlotinib Combined With Pemetrexed And Carboplatin as First-line Treatment in Advanced Nonsquamous NSCLC

Phase 1

Recruiting

NCT03778138 - Study of Anlotinib Combined With Pemetrexed in Patients With Advanced Nonsquamous NSCLC

Phase 2

Not yet recruiting

NCT03792074 - To Evaluate the Efficacy and Safety of SCT510 in the Treatment of Non-small Cell Lung Cancer

Phase 3

Interventional studies are often prospective and are specifically tailored to evaluate direct impacts of treatment or preventive measures on disease.

Observational studies are often retrospective and are used to assess potential causation in exposure-outcome relationships and therefore influence preventive methods.

Expanded access is a means by which manufacturers make investigational new drugs available, under certain circumstances, to treat a patient(s) with a serious disease or condition who cannot participate in a controlled clinical trial.

Clinical trials are conducted in a series of steps, called phases - each phase is designed to answer a separate research question.

Phase 1: Researchers test a new drug or treatment in a small group of people for the first time to evaluate its safety, determine a safe dosage range, and identify side effects.
Phase 2: The drug or treatment is given to a larger group of people to see if it is effective and to further evaluate its safety.
Phase 3: The drug or treatment is given to large groups of people to confirm its effectiveness, monitor side effects, compare it to commonly used treatments, and collect information that will allow the drug or treatment to be used safely.
Phase 4: Studies are done after the drug or treatment has been marketed to gather information on the drug's effect in various populations and any side effects associated with long-term use.

NCT number	NCT01673867
Study type	Interventional
Source	Bristol-Myers Squibb
Contact
Status	Completed
Phase	Phase 3
Start date	November 2, 2012
Completion date	December 17, 2021

Study of BMS-936558 (Nivolumab) Compared to Docetaxel in Previously Treated Metastatic Non-squamous NSCLC — CheckMate057

Clinical Trial Summary

Clinical Trial Description

Study Design

Related Conditions & MeSH terms